



**HAL**  
open science

## Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author’s reply

Djillali Annane, Lamiae Grimaldi-Bensouda, Véronique Fremeaux-Bacchic

### ► To cite this version:

Djillali Annane, Lamiae Grimaldi-Bensouda, Véronique Fremeaux-Bacchic. Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author’s reply. *EClinicalMedicine*, 2021, 35, pp.100866. 10.1016/j.eclinm.2021.100866 . hal-03217209

**HAL Id: hal-03217209**

**<https://hal.sorbonne-universite.fr/hal-03217209v1>**

Submitted on 4 May 2021

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



## Letter

## Complement inhibition in severe COVID-19 – Blocking C5a seems to be key: Author's reply

Djillali Annane<sup>a,\*</sup>, Lamiae Grimaldi-Bensouda<sup>b</sup>, Véronique Fremeaux-Bacchi<sup>c</sup>

<sup>a</sup> Department of Intensive Care, Hôpital Raymond Poincaré (APHP), Laboratory of Infection & Inflammation \_ U1173, School of Medicine Simone Veil, University Versailles Saint Quentin \_ University Paris Saclay, INSERM, FHU SEPSIS (Saclay and Paris Seine Nord Endeavour to Personalize Interventions for Sepsis), RHU RECORDS (Rapid rEcognition of CORticosteroid resistant or sensitive Sepsis), 104 Boulevard Raymond Poincaré, Garches 92380, France

<sup>b</sup> Clinical Research Unit AP-HP, Paris-Saclay, Hôpital Raymond Poincaré, School of Medicine Simone Veil, University Versailles Saint Quentin, University Paris, Saclay, INSERM, CESP Anti-Infective Evasion and Pharmacoepidemiology Team, F-78180 Montigny-Le-Bretonneux, France

<sup>c</sup> Laboratory of Immunology, Georges-Pompidou European Hospital (APHP), Invasive Bacterial Infection Unit and National Reference Center for Meningococci, Pasteur, Institute, Centre de Recherche des Cordeliers, Paris, France

## ARTICLE INFO

## Article History:

Received 2 April 2021

Accepted 8 April 2021

We thank Lim and colleagues [1] for questioning how best to modulate complement pathway to improve outcomes of patients with COVID-19. In our study, we found that in patients with severe COVID-19, eculizumab treatment associated reduction in soluble C5b-9 paralleled the reduction of the concentrations of circulating proinflammatory cytokines and arterial lactate [2]. To explore the effects of eculizumab treatment on the second limb of the terminal complement pathway, we retrospectively measured C5a concentrations at baseline, day-1 and day-7 in 44/80 patients (14/45 and 30/35 in the eculizumab free and treated, respectively). At baseline, C5a concentrations varied fairly from 7 to 200 ng/mL. In the eculizumab treated patients C5a median (IQR) concentrations were 38 (19–89) ng/mL, 24 (17–38) ng/mL and 24 (15–56) ng/mL, at baseline, day-1 and day-7, respectively (Kruskal-Wallis,  $P = 0.72$ ). The median concentrations of C5a did not statistically differ between eculizumab-treated and eculizumab-free patients at day-1 (Wilcoxon test,  $P = 0.93$ ) and day-7 ( $P = 0.14$ ). The reason for incomplete terminal pathway inhibition by eculizumab in patients with severe COVID-19 is unclear. These findings may contrast with eculizumab associated reduction in systemic and lung inflammation, and survival improvement. This retrospective analysis may lack of sufficient power as samples were missing for about one out of 2 patients. On the other hand, strong activation of complement may have played a role in

insufficient inhibition of the terminal complement pathway by eculizumab as previously suggested in complement-mediated diseases [3]. Median concentrations of C3a was 338 ng/mL (IQR: 194–718). Further studies may clarify the potential benefit of monoclonal antibodies targeting specifically C5a [4] or C5aR1 [5] in patients with severe COVID-19.

### Declaration of Competing Interest

Djillali Annane and Lamiae Grimaldi-Bensouda have no conflicts to declare. Veronique Fremeaux-Bacchi: reports non-financial support from Alexion Pharmaceuticals Inc. during the conduct of the study; grants and personal fees from Alexion, personal fees from Roche, personal fees from Apellis, and personal fees from Biocryps outside the submitted work.

### References

- [1] Lim EHT, Vlaar APJ, de Bruin S, Brouwer MC, van de Beek D, et al. Complement inhibition in severe COVID-19 – blocking C5a seems to be key. *EClinicalMedicine* 2020. doi: [10.1016/j.eclinm.2021.100722](https://doi.org/10.1016/j.eclinm.2021.100722).
- [2] Annane D, Heming N, Grimaldi-Bensouda L, et al. Eculizumab as an emergency treatment for adult patients with severe COVID-19 in the intensive care unit: a proof-of-concept study. *EClinicalMedicine* 2020. doi: [10.1016/j.eclinm.2020.100590](https://doi.org/10.1016/j.eclinm.2020.100590).
- [3] Harder MJ, Kuhn N, Schrezenmeier H, et al. Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activation. *Blood* 2017;129(8):970–80.
- [4] Vlaar APJ, de Bruin S, Busch M, et al. Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial. *Lancet Rheumatol* 2020. doi: [10.1016/S2665-9913\(20\)30341-6](https://doi.org/10.1016/S2665-9913(20)30341-6).
- [5] Carvelli J, Demaria O, Vély F, et al. Association of COVID-19 inflammation with activation of the C5a–C5aR1 axis. *Nature* 2020;588:146–50.

DOI of original article: <http://dx.doi.org/10.1016/j.eclinm.2020.100590>, <http://dx.doi.org/10.1016/j.eclinm.2021.100722>.

\* Corresponding author.

E-mail address: [Djillali.annane@aphp.fr](mailto:Djillali.annane@aphp.fr) (D. Annane).

<https://doi.org/10.1016/j.eclinm.2021.100866>

2589-5370/© 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>)